Human donors targeting the postfusion RSV F protein using human hybridoma technology
Alternative Names:
RSV, Orthopneumovirus,
Reactivity Species : Respiratory Syncytial<_Virus Expression Host : HEK-293 Endotoxin Level : 1.0 EU/mg as determined by the LAL method Specificity : RSV-14N4 activity is directed against antigenic site II of the RSV fusion (F) protein. RSV-14N4 readily competes with clone RSV-12I1 on post-fusion F, but the competition is less pronounced on prefusion F. A plaque reduction neutralization assay showed RSV-14N4 is capable of neutralizing RSV strain A2. By ELISA RSV-14N4 binds to both prefusion and post-fusion F proteins with equal affinity. Competition-binding studies showed that RSV-14N4 targets antigenic site II, which is the target of palivizumab, an antiviral monoclonal antibody used as a prophylactic treatment. Saturation alanine scanning mutagenesis identified residues Asp263, Ile266, Asp269, and Lys271 as critical for 14N4 binding. Binding to antigenic site II was confirmed by x-ray crystallography and electron microscopy as well as by binding to scaffolded epitopes containing site II.
Clonality:
Monoclonal
Clone Designation:
[RSV-14N4]
Purity:
>=95% monomer by analytical SEC
* VAT and and shipping costs not included. Errors and price changes excepted
